Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin

This publication has 40 references indexed in Scilit:

• Topical treatment of psoriatic plaques with 1,25-dihydroxyvitamin D3: a cell biological study
  British Journal of Dermatology, 1993
• Involvement of endogenously produced 1,25-dihydroxyvitamin D-3 in the growth and differentiation of human keratinocytes
  Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1991
• 1,25(OH)2-D3 is a potent regulator of interleukin-1 induced interleukin-8 expression and production
  Biochemical and Biophysical Research Communications, 1991
• Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris
  The Lancet, 1991
• Localization of Neutrophil-Activating Peptide-1/Interleukin-8-Immunoreactivity in Normal and Psoriatic Skin
  Journal of Investigative Dermatology, 1991
• DNA content and Ks8.12 binding of the psoriatic lesion during treatment with the vitamin D3 nalogue MC903 and betamethasone
  British Journal of Dermatology, 1990
• Mechanism of elongation of primed DNA by DNA polymerase delta, proliferating cell nuclear antigen, and activator 1.
  Proceedings of the National Academy of Sciences, 1990
• The immunobiology ofvitamin D: William F.C. Rigby
  Immunology Today, 1988
• A novel approach for the evaluation and treatment of psoriasis: Oral or topical use of 1,25-dihydroxyvitamin D3 can be a safe and effective therapy for psoriasis
  Journal of the American Academy of Dermatology, 1988
• Vitamin D and Epidermal Differentiation: Evidence for a Role of Endogenously Produced Vitamin D Metabolites in Keratinocyte Differentiation
  Skin Pharmacology and Physiology, 1988